Baseline modified Glasgow prognostic score associated with survival in metastatic urothelial cell carcinoma treated with immune checkpoint inhibitors

CONCLUSIONS: The mGPS may be a useful prognostic tool in mUC patients when treatment with ICI is under consideration. These results warrant a larger study for validation.IMPLICATIONS FOR PRACTICE: The ideal prognostic tool for use in a busy clinical practice is easy-to-use, cost-effective, and capable of accurately predicting clinical outcomes. There is currently no universally accepted risk score in metastatic urothelial cell carcinoma (mUC), particularly in the immunotherapy era. The modified Glasgow prognostic score (mGPS) incorporates albumin and C-reactive protein and may reflect underlying chronic inflammation, a known risk factor for resistance to immune checkpoint inhibitors (ICI). We found that baseline mGPS is associated with survival outcomes in patients with mUC treated with ICI and may help clinicians to prognosticate for their patients beginning immunotherapy.PMID:33634507 | DOI:10.1002/onco.13727

Source: The Oncologist - February 26, 2021 Category: Cancer & Oncology Authors: Jacqueline T Brown Yuan Liu Julie M Shabto Dylan J Martini Deepak Ravindranathan Emilie Elise Hitron Greta Anne Russler Sarah Caulfield Lauren Beth Yantorni Shreyas S Joshi Haydn Kissick Kenneth Ogan Wayne B Harris Bradley C Carthon Omer Kucuk Viraj A Mas Source Type: research